Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.
6 affiliations
- 1Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-ro Seongbuk-gu, Seoul, 02841, Republic of Korea.
- 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
- 3Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 07345, Republic of Korea.
- 4Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 06591, Seoul, Republic of Korea.
- 5Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea.
- 6Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea. [email protected].
Abstract
Glofitamab, a CD20×CD3 bispecific antibody, has shown durable activity in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL), but real-world data from Korean patients and after CAR-T failure remain limited. We retrospectively analyzed 46 patients with RR-DLBCL treated with glofitamab monotherapy. Response and safety were assessed in all patients, whereas the main survival and prognostic analyses were conducted in the non-bridge-intent cohort (n = 41), excluding five bridge-intent patients. Median age was 57.5 years; patients had received a median of three prior lines, and 58.7% had failed prior CAR-T. In the overall cohort, the objective response rate was 39.1% and the complete response rate was 32.6%. In the non-bridge-intent cohort, median progression-free survival (PFS) and overall survival (OS) were 2.6 and 5.9 months, respectively, after a median follow-up of 8.2 months. Median duration of response was not reached, and 10 of 15 responders remained in response. Prior CAR-T exposure was not associated with PFS or OS. A longer pre-glofitamab interval was associated with improved PFS (adjusted hazard ratio 0.51 per category increase; p = 0.018), but not OS. Patients with an interval < 1 month had an ORR of 15.4% and median PFS of 1.0 month. Cytokine release syndrome occurred in 26.1%, all Grade 1 or 2; no immune effector cell-associated neurotoxicity syndrome or treatment-related deaths occurred. Glofitamab monotherapy demonstrated clinically meaningful activity and manageable safety in heavily pretreated RR-DLBCL. In exploratory analyses, a shorter pre-glofitamab treatment interval was associated with poorer outcomes; this hypothesis-generating observation requires prospective validation.
Related
- 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
- Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review
- EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study
- PD-1-based combination therapy versus monotherapy in relapsed or refractory classical Hodgkin lymphoma: a single-center retrospective cohort study
- MAJESTEC-9: A PHASE 3 RANDOMIZED STUDY OF TECLISTAMAB MONOTHERAPY VS INVESTIGATOR’S CHOICE OF POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE OR CARFILZOMIB AND DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
BibTeX
@article{kim2026realworld,
title = {{Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.}},
author = {Changgon Kim and Youngil Koh and Youngwoo Jeon and Yoon Seok Choi and Seok Jin Kim and Won Seog Kim and Sang Eun Yoon},
journal = {Annals of hematology},
year = {2026},
month = aug,
doi = {10.1007/s00277-026-07212-9},
url = {https://europepmc.org/article/MED/42955341},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.
AU - Changgon Kim
AU - Youngil Koh
AU - Youngwoo Jeon
AU - Yoon Seok Choi
AU - Seok Jin Kim
AU - Won Seog Kim
AU - Sang Eun Yoon
PY - 2026
DA - 2026/08/01
JO - Annals of hematology
DO - 10.1007/s00277-026-07212-9
UR - https://europepmc.org/article/MED/42955341
AB - Glofitamab, a CD20×CD3 bispecific antibody, has shown durable activity in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL), but real-world data from Korean patients and after CAR-T failure remain limited. We retrospectively analyzed 46 patients with RR-DLBCL treated with glofitamab monotherapy. Response and safety were assessed in all patients, whereas the main survival and prognostic analyses were conducted in the non-bridge-intent cohort (n = 41), excluding five bridge-intent patients. Median age was 57.5 years; patients had received a median of three prior lines, and 58.7% had failed prior CAR-T. In the overall cohort, the objective response rate was 39.1% and the complete response rate was 32.6%. In the non-bridge-intent cohort, median progression-free survival (PFS) and overall survival (OS) were 2.6 and 5.9 months, respectively, after a median follow-up of 8.2 months. Median duration of response was not reached, and 10 of 15 responders remained in response. Prior CAR-T exposure was not associated with PFS or OS. A longer pre-glofitamab interval was associated with improved PFS (adjusted hazard ratio 0.51 per category increase; p = 0.018), but not OS. Patients with an interval < 1 month had an ORR of 15.4% and median PFS of 1.0 month. Cytokine release syndrome occurred in 26.1%, all Grade 1 or 2; no immune effector cell-associated neurotoxicity syndrome or treatment-related deaths occurred. Glofitamab monotherapy demonstrated clinically meaningful activity and manageable safety in heavily pretreated RR-DLBCL. In exploratory analyses, a shorter pre-glofitamab treatment interval was associated with poorer outcomes; this hypothesis-generating observation requires prospective validation.
SN - 0939-5555
SN - 1432-0584
ER -